Skip Ribbon Commands
Skip to main content
Clin Asst Prof Tuan Kit Loong Jeffrey

Clin Asst Prof Tuan Kit Loong Jeffrey

MBBS (Singapore), MSc (UK), FRCR (Clinical Oncology) (UK), FAMS

Senior Consultant

National Cancer Centre Singapore

Specialty: Radiation Oncology, Radiation Oncology

Clinical Interest: Uro-Oncology, Gynae-Oncology

Clinical Appointments

  • Senior Consultant, Research Director Division of Radiation Oncology National Cancer Centre SingaporeNational Cancer Centre Singapore
  • Head Department of Gastrointestinal Hepato-pancreato-biliary and Urology Division of Radiation Oncology National Cancer Centre SingaporeNational Cancer Centre Singapore
  • Visiting Consultant Urology Singapore General HospitalSingapore General Hospital
  • Visiting Consultant KK Gynaecological Cancer Centre KK Women's and Children's HospitalKK Women's and Children's Hospital
  • Institutional Representative National Cancer Centre SingaporeNational Cancer Centre Singapore

Academic Appointments

  • Clinical Asst Professor SingHealth Duke-NUS Oncology Academic Clinical Programme
  • Clinical Teacher, NTU-Lee Kong Chian, School of Medicine


Dr. Jeffrey Tuan is Head and Senior Consultant Radiation Oncologist of the Department of Gastrointestinal Hepato-Pancreato-Biliary and Urology and Research Director in the Division of Radiation Oncology at the National Cancer Centre Singapore. His clinical interests are in managing patients with Urological and Gyne-cological cancers using advanced radiation therapy techniques such as Intensity Modulated Volumetric Arc Radiotherapy, Stereotactic Body Radiotherapy (SBRT) and LDR/HDR Brachytherapy.  His current research interests are in intra-fractional tumor tracking, focal therapy in prostate cancer and identifying potential bi-omarkers in radiation sensitivity.  He holds a concurrent appointment as a Clinical Assistant Professor within the Oncology Academic Clinical Program in Duke – National University Singapore (Duke-NUS) and Clinical Teacher of the Nanyang Technological University Lee Kong Chian (NTU LKC) School of Medicine. He spent four years training and pursuing academic research in both the United Kingdom and Italy in the fields of Clinical Oncology and Particle Beam Therapy.  More recently as the Technical Lead, he is actively involved in the planning and setting up of the new Proton Beam Therapy Centre co-located at the new National Cancer Centre Singapore to be ready in 2022-3.


  • MSc (University of London) 2009
  • FRCR Royal College of Radiologists, UK 2009
  • MBBS (National University of Singapore) 2000

Professional Appointments and Committee Memberships

  • Member, Singapore Cancer Society (SCS) Prostate Survivorship Advisory Board
  • Chairman, 2021 SCS prostate cancer awareness month (PCAM)


  • HMDP to Royal Marsden Hospital London UK for clinical oncology 2007-2009
  • EU Marie Curie Fellow in particle therapy, PARTNER network, Fondazione CNAO, Pavia Italy 2010-2012

Research Interests

  • Brachytherapy in prostate and gynecological cancers
  • Hypo fractionated radiotherapy and stereotactic body radiotherapy (SBRT)
  • Rectal spacer to reduce radiation proctitis and cost effectiveness analysis (CEA)
  • Proton Beam Therapy
  • Artificial Intelligence (AI) based auto segmentation and auto contouring of prostate and dominant intra prostatic lesions (DIL)
  • Trans perineal Ultrasound imaging of the prostate for localization and tracking
  • Trigger imaging and fiducials for prostate tracking
  • ADT related cardiotoxicity in prostate cancer


1. Tan JSH, Teh JYH, Tan LLY, Tan SXF, Li YQ, Tan TWK, Wang MLC, Kanesvaran R, Ong EHW, Tay KJ, Lee LS, Tuan JKL, Tan DYH, Chua MLK. Efficacy, toxicity, and \quality-of-life outcomes of ultrahypofractionated radiotherapy in patients with localized prostate cancer: A single-arm phase 2 trial from Asia. Asia Pac J Clin Oncol. 2021 Dec 14. doi: 10.1111/ajco.13742. Epub ahead of print. PMID:34908240.
2. Ong A, Knight K, Panettieri V, Dimmock M, Tuan JKL, Tan HQ, Master Z, Wright C. Application of an automated dose accumulation workflow in high-risk prostate cancer - validation and dose-volume analysis between planned and delivered dose. Med Dosim. 2021 Nov 2:S0958-3947(21)00084-4. doi: 10.1016/j.meddos.2021.09.004.Epub ahead of print. PMID: 34740517.
3. Tan YG, Quek SZH, Huang HH, Ho HSS, Yuen JSP, Tay KJ, Tuan JKL, Chen K. Serum testosterone levels and testosterone 'bounce' phenomenon predict response to novel anti-androgen therapies in castration-resistant prostate cancer. Urol
Oncol. 2021 Dec;39(12):829.e9-829.e17. doi: 10.1016/j.urolonc.2021.04.009. Epub 2021 May 20. PMID: 34023195.
4. Wong SMM, Sin SY, Lim LH, Nurul Tassha BMA, Lin J, Melissa K, Koh WY, Ho F, Quah DSC, Sommat K, Tuan JKL, Wong FY, Ng WL, Yeo RMC, Soong YL, Wang MLC. The implementation of an advanced practice radiation therapy (APRT) program in
Singapore. Tech Innov Patient Support Radiat Oncol. 2021 Mar 18;17:63-70. doi: 10.1016/j.tipsro.2021.02.002. PMID: 34007909; PMCID: PMC8111035.
5. Tey J, Ho F, Koh WY, Chia D, Ooi KH, Tuan JKL, Vellayappan B, Soon YY.Palliative radiotherapy for bladder cancer: a systematic review and meta-analysis. Acta Oncol. 2021 May;60(5):635-644. doi: 10.1080/0284186X.2021.1880025. Epub 2021 Feb 16. PMID: 33591843.
6. Kiljunen T, Akram S, Niemelä J, Löyttyniemi E, Seppälä J, Heikkilä J,Vuolukka K, Kääriäinen OS, Heikkilä VP, Lehtiö K, Nikkinen J, Gershkevitsh E, Borkvel A, Adamson M, Zolotuhhin D, Kolk K, Pang EPP, Tuan JKL, Master Z, Chua
MLK, Joensuu T, Kononen J, Myllykangas M, Riener M, Mokka M, Keyriläinen J. A Deep Learning-Based Automated CT Segmentation of Prostate Cancer Anatomy for Radiation Therapy Planning-A Retrospective Multicenter Study. Diagnostics (Basel). 2020 Nov 17;10(11):959. doi: 10.3390/diagnostics10110959. PMID:33212793; PMCID: PMC7697786.
7. Ong A, Knight K, Panettieri V, Dimmock M, Tuan JKL, Tan HQ, Master Z, Wright C. Development of an automated radiotherapy dose accumulation workflow for locally advanced high-risk prostate cancer - A technical report. J Med Radiat Sci. 2021 Jun;68(2):203-210. doi: 10.1002/jmrs.442. Epub 2020 Oct 15. PMID: 33058720; PMCID: PMC8168070.
8. Pang EPP, Knight K, Leung RW, Wang MLC, Chan JWS, Low GK, Seah IKL, Atan MAB, Chai JYH, Ng GC, Yang TC, Tuan JKL. Technical considerations for positioning and placement of a transperineal ultrasound probe during prostate radiotherapy. J Med Radiat Sci. 2021 Jun;68(2):196-202. doi: 10.1002/jmrs.439. Epub 2020 Oct 5.
PMID: 33017863; PMCID: PMC8168066.
9. Ng KYY, Zhou S, Tan SH, Ishak NDB, Goh ZZS, Chua ZY, Chia JMX, Chew EL, Shwe T, Mok JKY, Leong SS, Lo JSY, Ang ZLT, Leow JL, Lam CWJ, Kwek JW, Dent R, Tuan J, Lim ST, Hwang WYK, Griva K, Ngeow J. Understanding the Psychological Impact of COVID-19 Pandemic on Patients With Cancer, Their Caregivers, and Health Care Workers in Singapore. JCO Glob Oncol. 2020 Oct;6:1494-1509. doi: 10.1200/GO.20.00374. PMID: 33017179; PMCID: PMC7640379.
10. Tan BF, Tuan JKL, Yap SP, Ho SZ, Wang MLC. Managing the COVID-19 Pandemic as a National Radiation Oncology Centre in Singapore. Clin Oncol (R Coll Radiol). 2020 Jul;32(7):e155-e159. doi: 10.1016/j.clon.2020.04.006. Epub 2020 Apr 23.PMID: 32359846; PMCID: PMC7177121.
11. Tey J, Ho S, Choo BA, Ho F, Yap SP, Tuan JKL, Leong CN, Cheo T, Sommat K, Wang MLC. Navigating the challenges of the COVID-19 outbreak: Perspectives from the radiation oncology service in Singapore. Radiother Oncol.2020 Jul;148:189-193. doi: 10.1016/j.radonc.2020.03.030. Epub 2020 Mar 31. PMID: 32342873; PMCID: PMC7118656.
12. Pang EPP, Knight K, Park SY, Lian W, Master Z, Baird M, Chan JWX, Wang MLC, Tan TWK, Chua MLK, Chua ET, Looi WS, Nei WL, Tuan JKL. Duration-dependent margins for prostate radiotherapy-a practical motion mitigation strategy.
Strahlenther Onkol. 2020 Jul;196(7):657-663. doi: 10.1007/s00066-019-01558-y.Epub 2020 Jan 13. PMID: 31932995.
13. Tan JSH, Goh CXY, Koh YS, Li Y, Tuan JKL, Chua ET, Tan TWK, Wang MLC, Lee LS, Tay KJ, Kanesvaran R, Toh CK, Tong AKT, Lam WWC, Chua MLK. 68Gallium-labelled PSMA-PET/CT as a diagnostic and clinical decision-
making tool in Asian prostate cancer patients following prostatectomy. Cancer Biol Med. 2019 Feb;16(1):157-166. doi: 10.20892/j.issn.2095-3941.2018.0288. PMID: 31119056; PMCID: PMC6528443.
14. Ong ALK, Ang KW, Master Z, Wong SMM, Tuan JKL. Intensity-modulated radiotherapy for whole pelvis irradiation in prostate cancer: A dosimetric andplan robustness study between photons and protons. Tech Innov Patient Support
Radiat Oncol. 2018 Apr 3;6:11-19. doi: 10.1016/j.tipsro.2018.02.001. PMID: 32095573; PMCID: PMC7033791.
15. Pang EPP, Knight K, Fan Q, Tan SXF, Ang KW, Master Z, Mui WH, Leung RW, Baird M, Tuan JKL. Analysis of intra-fraction prostate motion and derivation ofduration-dependent margins for radiotherapy using real-time 4D ultrasound. Phys Imaging Radiat Oncol. 2018 Mar 28;5:102-107. doi: 10.1016/j.phro.2018.03.008. PMID: 33458378; PMCID: PMC7807728.

Research Trials

  • Outcomes Research in cancer care
  • Stereotactic body radiotherapy (SBRT) in prostate cancer
  • Low dose rate (LDR) brachytherapy in prostate cancer
  • High dose rate (HDR) brachytherapy in prostate cancer
  • Feasibility of dominant prostatic lesion (DIL) boosting/dose escalation with proton beam therapy